| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot; human; fig 4
| Park S, Jo D, Jo S, Shin D, Shim S, Jo Y, et al. Inhibition of never in mitosis A (NIMA)-related kinase-4 reduces survivin expression and sensitizes cancer cells to TRAIL-induced cell death. Oncotarget. 2016;7:65957-65967 pubmed publisher |
- western blot; mouse; loading ...; fig 4d
| Singh S, Chand H, Gundavarapu S, Saeed A, Langley R, Tesfaigzi Y, et al. HIF-1α Plays a Critical Role in the Gestational Sidestream Smoke-Induced Bronchopulmonary Dysplasia in Mice. PLoS ONE. 2015;10:e0137757 pubmed publisher |
- western blot; human; fig 4
| Sun Y, Ponz Sarvisé M, Chang S, Chang W, Chen C, Hsu J, et al. Proteasome inhibition enhances the killing effect of BikDD gene therapy. Am J Transl Res. 2015;7:319-27 pubmed |
| Choi C, Kwon J, Lim S, Helfman D. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer. Oncotarget. 2016;7:63466-63487 pubmed publisher |
| Xie X, Tang S, Cai Y, Pi W, Deng L, Wu G, et al. Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1. Oncotarget. 2016;7:58111-58120 pubmed publisher |
| Ho J, Hsu R, Wu C, Liao G, Gao H, Wang T, et al. Reduced miR-550a-3p leads to breast cancer initiation, growth, and metastasis by increasing levels of ERK1 and 2. Oncotarget. 2016;7:53853-53868 pubmed publisher |
| He L, Gao S, Zhu Z, Chen S, Gu H. Ikaros expression sensitizes leukemic cells to the chemotherapeutic drug doxorubicin. Oncol Lett. 2016;12:1178-1182 pubmed |
| Guan H, Xie L, Wirth T, Ushmorov A. Repression of TCF3/E2A contributes to Hodgkin lymphomagenesis. Oncotarget. 2016;7:36854-36864 pubmed publisher |
| Benvenuto M, Masuelli L, De Smaele E, Fantini M, Mattera R, Cucchi D, et al. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. Oncotarget. 2016;7:9250-70 pubmed publisher |
| Luey B, May F. Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway. Mol Cancer. 2016;15:8 pubmed publisher |
| Kim R, Suh Y, Yoo K, Cui Y, Kim H, Kim M, et al. Activation of KRAS promotes the mesenchymal features of basal-type breast cancer. Exp Mol Med. 2015;47:e137 pubmed publisher |
| Davis N, Sokolosky M, Stadelman K, Abrams S, Libra M, Candido S, et al. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget. 2014;5:4603-50 pubmed |
| Nagy Z, Kovacs I, Torok M, Tóth D, Vereb G, Buzas K, et al. Function of RasGRP3 in the formation and progression of human breast cancer. Mol Cancer. 2014;13:96 pubmed publisher |
| Rutkowski M, Allegrezza M, Svoronos N, Tesone A, Stephen T, Perales Puchalt A, et al. Initiation of metastatic breast carcinoma by targeting of the ductal epithelium with adenovirus-cre: a novel transgenic mouse model of breast cancer. J Vis Exp. 2014;: pubmed publisher |
| Gaur S, Chen L, Ann V, Lin W, Wang Y, Chang V, et al. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status. Mol Cancer. 2014;13:21 pubmed publisher |
| Muthuswami M, Ramesh V, Banerjee S, Viveka Thangaraj S, Periasamy J, Bhaskar Rao D, et al. Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition. PLoS ONE. 2013;8:e77553 pubmed publisher |
| Mehta R, Katta H, Alimirah F, Patel R, Murillo G, Peng X, et al. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS ONE. 2013;8:e65113 pubmed publisher |
| Kandouz M, Zhao J, Bier A, Di Marco S, Oviedo Landaverde I, Gallouzi I, et al. Post-transcriptional regulation of connexin43 in H-Ras-transformed cells. PLoS ONE. 2013;8:e58500 pubmed publisher |
| Engesæter B, Engebraaten O, Flørenes V, Mælandsmo G. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS ONE. 2012;7:e45492 pubmed publisher |
| Tanic M, Yanowsky K, Rodriguez Antona C, Andres R, Márquez Rodas I, Osorio A, et al. Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS ONE. 2012;7:e38847 pubmed publisher |
| Fathers K, Bell E, Rajadurai C, Cory S, Zhao H, Mourskaia A, et al. Crk adaptor proteins act as key signaling integrators for breast tumorigenesis. Breast Cancer Res. 2012;14:R74 pubmed |
| Toulany M, Schickfluss T, Eicheler W, Kehlbach R, Schittek B, Rodemann H. Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation. Breast Cancer Res. 2011;13:R28 pubmed publisher |
| Benbrahim Tallaa L, Tokar E, Diwan B, Dill A, Coppin J, Waalkes M. Cadmium malignantly transforms normal human breast epithelial cells into a basal-like phenotype. Environ Health Perspect. 2009;117:1847-52 pubmed publisher |
| Cheung M, Pei J, Pei Y, Jhanwar S, Pass H, Testa J. The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival. Oncogene. 2010;29:1633-40 pubmed publisher |
| Ulasov I, Sonabend A, Nandi S, Khramtsov A, Han Y, Lesniak M. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer. 2009;100:1154-64 pubmed publisher |
